StockNews.AI
NMRA
StockNews.AI
97 days

Kuehn Law Encourages Investors of Neumora Therapeutics, Inc. to Contact Law Firm

1. Kuehn Law is investigating NMRA's executive actions regarding fiduciary duties. 2. A federal lawsuit claims NMRA misrepresented crucial trial data to justify its Phase Three Program. 3. The lawsuit alleges inadequate patient population data in the Phase Two Trials. 4. Shareholders who purchased before September 15, 2023, are urged to act quickly. 5. Investor's voices matter in ensuring market integrity, according to Kuehn Law.

5m saved
Insight
Article

FAQ

Why Bearish?

The lawsuit's allegations can lead to increased scrutiny and potential liability for NMRA, reminiscent of past legal challenges faced by biotech firms that similarly misrepresented clinical trial results, which historically resulted in stock price declines.

How important is it?

The ongoing investigation and the associated federal lawsuit indicate serious allegations that can significantly affect NMRA's stock sentiment and pricing in the near term, motivating investors to reassess their positions based on potential legal outcomes.

Why Short Term?

The short-term horizon is driven by immediate market reactions to potentially negative legal developments, as seen previously during litigation announcements in the biotech sector that often cause swift share price declines.

Related Companies

VRTXREGNSNY
, /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Neumora Therapeutics, Inc. (NASDAQ: NMRA) breached their fiduciary duties to shareholders.  According to a federal securities lawsuit, Insiders at Neumora Therapeutics caused the company to misrepresent or fail to disclose (1) in order for Neumora to justify conducting its Phase Three Program, Neumora was forced to amend BlackThorn's original Phase Two Trial inclusion criteria to include a patient population with moderate to severe MDD to show that Navacaprant offered a statistically significant improvement in treating MDD; (2) and to that same end, the Company also added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD; and (3) the Phase Two Trials lacked adequate data, particularly in regards to the patient population size and the ratio of male to female patients within the patient population, to be able to accurately predict the results of the KOASTAL-1 study. If you currently own NMRA and purchased prior to September 15, 2023 please contact Justin Kuehn, Esq. here, by email at [email protected] or call (833) 672-0814.  Kuehn Law pays all case costs and does not charge its investor clients. Shareholders should contact the firm immediately as there may be limited time to enforce your rights.  Why Your Participation Matters: As a shareholder your voice matters, and by getting involved, you contribute to the integrity and fairness of the financial markets. Your investment. Your voice. Your future.™  For additional information, please visit Shareholder Derivative Litigation - Kuehn Law. Attorney advertising. Prior results do not guarantee similar outcomes. Contacts:Kuehn Law, PLLCJustin Kuehn, Esq.53 Hill Street, Suite 605Southampton, NY 11968[email protected](833) 672-0814 SOURCE Kuehn Law, PLLC WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News